Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/16483
Title: | Capture and on-chip analysis of melanoma cells using tunable surface shear forces | Austin Authors: | Tsao, Simon Chang-Hao;Vaidyanathan, Ramanathan;Dey, Shuvashis;Carrascosa, Laura G;Christophi, Christopher ;Cebon, Jonathan S ;Shiddiky, Muhammad JA;Behren, Andreas;Trau, Matt | Affiliation: | Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia Department of Surgery - Austin Health, University of Melbourne, Heidelberg, Victoria, Australia Ludwig Institute for Cancer Research - Austin Health, Heidelberg, Victoria, Australia Centre for Personalised NanoMedicine, Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Brisbane, Queensland, Australia School of Cancer Medicine- La Trobe University, Melbourne, Victoria, Australia School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Queensland, Australia |
Issue Date: | Jan-2016 | Publication information: | Scientific Reports 2016; 6: 19709 | Abstract: | With new systemic therapies becoming available for metastatic melanoma such as BRAF and PD-1 inhibitors, there is an increasing demand for methods to assist with treatment selection and response monitoring. Quantification and characterisation of circulating melanoma cells (CMCs) has been regarded as an excellent non-invasive candidate but a sensitive and efficient tool to do these is lacking. Herein we demonstrate a microfluidic approach for melanoma cell capture and subsequent on-chip evaluation of BRAF mutation status. Our approach utilizes a recently discovered alternating current electrohydrodynamic (AC-EHD)-induced surface shear forces, referred to as nanoshearing. A key feature of nanoshearing is the ability to agitate fluid to encourage contact with surface-bound antibody for the cell capture whilst removing nonspecific cells from the surface. By adjusting the AC-EHD force to match the binding affinity of antibodies against the melanoma-associated chondroitin sulphate proteoglycan (MCSP), a commonly expressed melanoma antigen, this platform achieved an average recovery of 84.7% from biological samples. Subsequent staining with anti-BRAF(V600E) specific antibody enabled on-chip evaluation of BRAF(V600E) mutation status in melanoma cells. We believe that the ability of nanoshearing-based capture to enumerate melanoma cells and subsequent on-chip characterisation has the potential as a rapid screening tool while making treatment decisions. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/16483 | DOI: | 10.1038/srep19709 | Journal: | Scientific Reports | PubMed URL: | https://pubmed.ncbi.nlm.nih.gov/26815318 | Type: | Journal Article |
Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.